A phase II study of ATB-346 in patients with osteoarthritis

Trial Profile

A phase II study of ATB-346 in patients with osteoarthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs ATB 346 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 08 Aug 2016 Primary endpoint (reduction in WOMAC pain scores) has been met, according to an Antibe Therapeutics media release.
    • 08 Aug 2016 Results published in an Antibe Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top